Collegium Pharmaceutical opened higher at $25.06, compared with its previous close of $24.81. In the last trading session, the stock traded between $24.52 and $25.13. It showed a sideways intraday trend.
An investment of $100 made 5 years ago in Collegium Pharmaceutical is now worth
$ 124.13
Giving a profit of
$ 24.13 (24.13%)
Note: Past profits do not guarantee future returns.
Rating from 6 Analysts
Today's Change
+$0.17 (+0.67%)
Day High
$25.13
Day Low
$24.52
Day Open
$25.06
Prev Close
$24.81
Volume
3,46,312
1W Return
5.59%
1M Return
13.21%
3M Return
-3.73%
6M Return
-30.26%
1Y Return
-44.30%
Market Cap ($ Mn)
776
PE Ratio
19.96
PB Ratio
2.64
PEG Ratio
1.69
ROE
24.71%
ROCE
14.11%
EPS (TTM)
$0.70
1 Week
5.59%
1 Month
13.21%
3 Months
-3.73%
6 Months
-30.26%
9 Months
-44.67%
Piper Sandler cuts Collegium Pharmaceutical price target to $28
Piper Sandler lowers Collegium Pharmaceutical's price target to $28. Previous price target was set at $43. Analyst David Amsellem maintains a Neutral rating.
6 days agoNeedham maintains Buy on Collegium, cuts price target to $44
Needham maintains a Buy rating on Collegium Pharmaceutical. Price target lowered from $46 to $44. Analyst Serge Belanger issued the revised rating.
7 days agoCollegium pays $17 million to settle Grünenthal patent dispute
Collegium Pharmaceutical pays $17,000,000 to settle patent infringement claims with Grünenthal. The settlement terminates the Grünenthal License and discharges all future royalty obligations. Grünenthal assigns certain Nucynta-related patents to Collegium as part of the agreement. The Nucynta Litigation in the District of New Jersey is resolved via a motion to dismiss.
24 days agoCollegium Pharmaceutical Q2 2026 revenue up 6% to $199.9 million
Total net product revenues rose 6% YoY to $199.9 million in Q2 2026, with non-GAAP adjusted EBITDA up 8% YoY to $113.8 million. Jornay PM net revenue grew 41% YoY to $46.1 million, with prescribers reaching an all-time high of over 30,000 healthcare providers. Azstarys acquisition closed in May; revenues of $12.9 million reflect approximately a month and a half of commercial sales. Nucynta franchise net revenue fell 24% YoY to $35.2 million due to lower net pricing on authorised generics, prompting a guidance revision. Updated 2026 guidance sets total net product revenues at $825 million to $855 million and Azstarys revenues at $65 million to $75 million.
1mo agoCollegium Pharmaceutical relocates headquarters to Boston in Q1 2027
Collegium Pharmaceutical will relocate its corporate headquarters to One Lincoln in Boston in Q1 2027 to enhance engagement with the life sciences community and support growth. The move reinforces the company's commitment to Massachusetts, where it has been based for over two decades. DivcoWest owns the new property, and Avison Young advised on the transaction.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,437.29 | +0.35% | $13,52,123.38M | 39.43 | |
| $280.41 | -0.13% | $6,75,033.80M | 31.06 | |
| $294.98 | +0.37% | $5,21,411.37M | 72.17 | |
| $147.18 | -0.59% | $3,62,834.91M | 117.74 | |
| $160.32 | -1.80% | $3,26,222.34M | 23.23 | |
| $185.48 | -0.69% | $2,87,691.54M | 24.32 | |
| $468.11 | +0.62% | $2,53,205.85M | 26.86 | |
| $169.73 | -0.67% | $2,10,522.74M | - | |
| $29.45 | +0.31% | $1,67,860.70M | 36.79 | |
| $41.09 | +0.96% | $1,39,300.36M | 11.15 | |
| $62.91 | +0.18% | $1,28,593.45M | 14.67 | |
| $48.43 | +0.41% | $1,16,984.89M | 23.63 |
An investment of $100 made 5 years ago in Collegium Pharmaceutical is now worth
$ 124.13
Giving a profit of
$ 24.13 (24.13%)
Note: Past profits do not guarantee future returns.
